Opacification is the filling of an echo free region, such as a ventricular cavity, with echoes from microbubble contrast.

(LVO) Ultrasound contrast agents improve the echocardiography assessment of left ventricular function and the low sensitivity of changes in left ventricular ejection fraction (LVEF). In addition, harmonic imaging techniques and automated border detection (ABD) together with contrast enhanced left ventricular opacification increase endocardial border delineation (EBD) and the results compared to native echocardiography.

EchoGen® is a fluorocarbon-based (dodecafluoropentane) third generation USCA. EchoGen® consists of microbubbles stabilized with surfactants in a phase shift colloid emulsion (perflenapent). EchoGen® requires no preparation, reconstitution, or refrigeration.
Perflenapent emulsion would represent a significant advance in contrast echocardiography caused by effective and long lasting opacification of the left ventricle and enhanced endocardial border delineation.
The persistence of the contrast effect permits interrogation in multiple echocardiographic views, as well as the visualization and localization of myocardial perfusion deficits at rest by producing a negative contrast effect.
October 12, 2000
Sonus Pharmaceuticals, Inc. announced a strategic decision to refocus the Company on the development of its drug delivery and blood substitute products. At the same time, Sonus has withdrawn the NDA (New Drug Application) and discontinued clinical activity for its ultrasound contrast product, EchoGen®.
August 06, 2001
Sonus Pharmaceuticals, Inc. announced that it has entered into an agreement to sell its ultrasound contrast assets for $6.5 million to Amersham plc. As part of the agreement, Sonus has also assigned to Nycomed its interest in the ultrasound contrast patent license agreement entered into with Chugai Pharmaceutical Co. Ltd. and Molecular Biosystems Inc in January 2001.

Quantison, consisting of air-filled microbubbles with stiff and rigid human serum albumin shells, is an investigational ultrasound contrast agent for the assessment of coronary artery disease.
The stiff shell inhibits the bubbles from oscillating and decrease non-linear scattering. Quantison is capable of long lasting cavity contrast and myocardial opacification using intermittent imaging.

Vascular ultrasound obtains images and measures blood flow velocity in the carotids, abdominal aorta, and vessels of kidneys, arms, or legs. Blockages in arteries, blood clots in veins, or abdominal aortic aneurysm can be detected.
These abnormalities in blood flow are usually examined with different Doppler techniques. In addition, the speed and direction of blood flow can be color coded in a color map. Duplex techniques show both, the vessels and the surrounding tissue. The use of ultrasound contrast agents improves the left ventricular opacification in cardiac ultrasound examination. Usually, for a vascular ultrasound no special preparation is needed.

See also Echocardiography, Venous Ultrasound, Adventitia, Intima, Temporal Mean Velocity, and Intravascular Ultrasound.